During a meeting in Canberra on 15 September 2026, representatives of the United Kingdom and Australia confirmed their commitment to continue cooperation across the life‑sciences ecosystem. The two governments highlighted the importance of this partnership for improving health outcomes, driving innovation‑led growth, attracting investment and creating high‑value jobs.
Both sides recognise their world‑class capabilities in health and medical research, clinical development, biotechnology innovation, advanced manufacturing and commercialisation. They agreed to connect researchers, clinicians, regulators, investors and industry to translate scientific discoveries into safe and effective products, services and treatments that benefit patients and support economic growth.
Key areas of cooperation include clinical trials, genomics and precision medicine, biotechnology innovation, digital health, advanced therapies, regulatory excellence and pathways to commercialisation. The collaboration aims to support more efficient development pathways, stronger partnerships and greater opportunities for innovative companies in both markets.
Regulatory bodies – the Therapeutic Goods Administration (TGA) and the Medicines and Healthcare products Regulatory Agency (MHRA) – will continue to collaborate bilaterally and through the Access Consortium, the International Coalition of Medicines Regulatory Authorities and the International Medical Device Regulators Forum. They will share experience on novel regulatory approaches and support access to innovative health products.
Austrade and the UK Department for Business, Innovation, Science and Trade will promote bilateral trade, investment, innovation, market access and company connections across shared priorities, including clinical trials, genomics, health data, digital health, biotechnology, medical technology and advanced therapies.